Arce HAA, Villaescusa BR, Merlín LJC, Guerreiro HAM, Leyva RA, Lam DRM, Hernández PC

Language: Spanish
References: 12
Page: 359-363
PDF size: 62.42 Kb.

ABSTRACT

Introduction: The involvement of adhesion molecules in erythrocytes with hemoglobin SS, in vascular endothelium and also plasma factors have been shown in the vasoocclusion phenomenon in sickle cell anemia (SCA). Band 3 refers to a family of anion exchangers present in the membrane of all cells and cellular organelles which under certain conditions cluster on the erythrocyte surface being recognized by natural antibodies as part of the mechanism of removal of senescent or oxidized erythrocytes.
Objective: To evaluate the possible participation of natural anti band 3 antibodies in the occlusive phenomenon in SCA.
Methods: A follow up study to determine the presence of natural band 3 antibodies in 19 patients with SCA in different clinical stages was performed using an enzyme immunoassay in microplates coupled with the band 3 protein.
Results: Significant low levels (p ‹ 0.01) of natural band 3 antibodies were demonstrated in the samples of patients obtained in painful vasoocclusive crisis stages, decrease which may be related to a high consumption of antibodies in the process of removing oxidized SS erythrocytes from blood circulation. Steady state samples were within normal range.
Conclusion: The results suggest the involvement of natural band 3 antibodies in the regulation of the adherence of SS erythrocytes to vascular endothelium in SCA.

REFERENCES

1. Rees DC, Gibson JS Biomarkers in Sickle cell disease. Br J Haematol. 2012;156:433-45

2. Steinberg MH. In the clinic. Sickle cell disease. Ann Intern Med. 2011;155(5):1-15.

3. Gutsaeva DR, Parkerson JB, Yerigenahally SD. Inhibition of cell adhesion by anti-Pselectin aptamer: a new potential therapeutic agent for sickle cell disease. Blood. 2011; 117(2):727-735.

4. Manwami D, Frenette PS. Vaso-oclusion in sickle cell disease: pathophysiology and novel targeted therapies. ASH Education Book. 2013;1:362-9. Doi:10.1182/asheducation-2013.1.362

5. Kutlar A, Ataga KI, McMahon L. A potent oral P-selectin blocking agent improves microcirculatory blood flow and a marker of endothelial cell injury in patients with sickle cell disease. Am J Hematol. 2012;87(5):536-539.

6. Rees DC, Williams TN, Gladwin MT. Sickle-cell disease. Lancet. 2010;376:2018-31

7. Arce AA, Villaescusa R. Organización de la membrana celular: banda 3, estructura y function. Rev Cubana Hematol Inmunol Hemoter. 2005 [citado 2015 Abr 23];21(3). Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid= S0864-02892005000300001&lng=es .

8. Arese P, Turrini F, Schwarzer E. Band 3/complement-mediated recognition and removal of normally senescent and pathological human erythrocytes. Cellular Physiol Biochem. 2005;16(4):133-46.

9. Arce AA, Villaescusa R, Merlín JC. Ensayo inmunoenzimático para la determinación de anticuerpos naturales anti banda 3. Rev Cubana Hematol Inmunol Hemoter [Internet]. 2008 Dic [citado 2015 Abr 23] ;24(3). Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S0864- 02892008000300006&lng=es .

10. Kaul DK, Finnegan E, Barabino GA. Sickle red cell-endothelium interactions. Microcirculation. 2009;16(1):97-111.

11. Kaul DK. Insights into vascular pathobiology of sickle cell disease. Hematology 2009;15:446-57.

12. Villaescusa R, Arce AA, Lalanne-Mistrih ML, Lamarre Y, Hierso R, Hernández C, Hardy-Dessources MD, CAREST study group. Natural anti band 3 antibodies in patients with sickle cell disease. CR Biologies. 2013;336:173-6.